title: Influenza vaccination in systemic lupus erythematosus: safe and protective?
abstract: Patients with systemic lupus erythematosus (SLE) show decreased immune responsiveness and are vulnerable for infectious diseases, due to the underlying disease and the frequent use of immunosuppressive drugs. Influenza has a high incidence in the population and is associated with increased morbidity and mortality in immunocompromised patients. Therefore, routine influenza vaccination of SLE patients seems indicated. However, there have been concerns about the safety of influenza vaccination in SLE as vaccination was thought to activate the autoimmune response. Safety of influenza vaccination has been studied, and, as far as SLE patients with quiescent disease are concerned, it is now generally accepted that influenza vaccination is safe. Another point of concern is vaccine efficacy. In immunocompromised patients, the immunogenicity of vaccines may be reduced. In the immune response to influenza (vaccination) both humoral and cell-mediated responses are involved. In SLE, research on the immune response to influenza vaccination has focused on humoral immune responses, demonstrating a blunted humoral response. Future research should focus on cell-mediated immune responses as well, as these are important for clearing of influenza infection and are expected to be impaired in SLE. Because of the decreased immunogenicity of the current influenza vaccine in SLE, new influenza vaccination strategies should be explored to improve vaccination efficacy.
authors.affiliation: Department of Clinical Immunology, University Medical Center Groningen, University of Groningen, The Netherlands. B.Holvast@int.umcg.nl
authors.forename: Bert
authors.initials: B
authors.lastname: Holvast
authors.forename: Anke
authors.initials: A
authors.lastname: Huckriede
authors.forename: Cees G M
authors.initials: CG
authors.lastname: Kallenberg
authors.forename: Marc
authors.initials: M
authors.lastname: Bijl
mesh_terms: D000917:Antibody Formation; D006801:Humans; D007111:Immunity, Cellular; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology / Q000821:virology; D018448:Models, Immunological; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000009:adverse effects
chemical_list: D007252:Influenza Vaccines